These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 31353502

  • 1. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma.
    Kim HD, Park S, Jeong S, Lee YJ, Lee H, Kim CG, Kim KH, Hong SM, Lee JY, Kim S, Kim HK, Min BS, Chang JH, Ju YS, Shin EC, Song GW, Hwang S, Park SH.
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F, Zeng G, Zhou S, He X, Sun N, Zhu X, Hu A.
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.
    Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Seo SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC.
    Cancer Lett; 2021 Feb 28; 499():137-147. PubMed ID: 33249194
    [Abstract] [Full Text] [Related]

  • 6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.
    Gastroenterology; 2017 Oct 28; 153(4):1107-1119.e10. PubMed ID: 28648905
    [Abstract] [Full Text] [Related]

  • 7. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma.
    Ge Z, Zhou G, Campos Carrascosa L, Gausvik E, Boor PPC, Noordam L, Doukas M, Polak WG, Terkivatan T, Pan Q, Takkenberg RB, Verheij J, Erdmann JI, IJzermans JNM, Peppelenbosch MP, Kraan J, Kwekkeboom J, Sprengers D.
    Cell Mol Gastroenterol Hepatol; 2021 Oct 28; 12(2):443-464. PubMed ID: 33781741
    [Abstract] [Full Text] [Related]

  • 8. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.
    Wan YL, Zheng SS, Zhao ZC, Li MW, Jia CK, Zhang H.
    World J Gastroenterol; 2004 Jan 15; 10(2):195-9. PubMed ID: 14716821
    [Abstract] [Full Text] [Related]

  • 9. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.
    Moreno-Cubero E, Subirá D, Sanz-de-Villalobos E, Parra-Cid T, Madejón A, Miquel J, Olveira A, González-Praetorius A, García-Samaniego J, Larrubia JR.
    J Virol; 2018 Jan 15; 92(2):. PubMed ID: 29093082
    [Abstract] [Full Text] [Related]

  • 10. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma.
    Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, Li T, Zhu F, Ma L, Zhang Z, Zhang S, Duan M, Chen Q, Gao Q, Zhang X.
    J Immunother Cancer; 2019 Nov 29; 7(1):331. PubMed ID: 31783783
    [Abstract] [Full Text] [Related]

  • 11. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.
    J Immunother; 2011 Apr 29; 34(3):236-50. PubMed ID: 21389874
    [Abstract] [Full Text] [Related]

  • 12. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG, Kim G, Kim KH, Park S, Shin S, Yeo D, Shim HS, Yoon HI, Park SY, Ha SJ, Kim HR.
    J Immunother Cancer; 2021 Dec 29; 9(12):. PubMed ID: 34907028
    [Abstract] [Full Text] [Related]

  • 13. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI, Rhodin KE, Dechant C, Cui X, Chongsathidkiet P, Wilkinson D, Waibl-Polania J, Sanchez-Perez L, Fecci PE.
    Clin Cancer Res; 2020 Mar 15; 26(6):1349-1358. PubMed ID: 31871298
    [Abstract] [Full Text] [Related]

  • 14. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma.
    Park J, Kwon M, Kim KH, Kim TS, Hong SH, Kim CG, Kang SG, Moon JH, Kim EH, Park SH, Chang JH, Shin EC.
    Clin Cancer Res; 2019 Apr 15; 25(8):2549-2559. PubMed ID: 30659023
    [Abstract] [Full Text] [Related]

  • 15. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma.
    Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH.
    Gastroenterology; 2018 Dec 15; 155(6):1936-1950.e17. PubMed ID: 30145359
    [Abstract] [Full Text] [Related]

  • 16. PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15.
    Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, Ahn MJ, Shin EC.
    Cell Mol Immunol; 2021 Feb 15; 18(2):385-397. PubMed ID: 32332901
    [Abstract] [Full Text] [Related]

  • 17. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers.
    Park J, Kim JC, Lee YJ, Kim S, Kim SW, Shin EC, Lee JY, Park SH.
    J Immunother Cancer; 2024 Jul 04; 12(7):. PubMed ID: 38964784
    [Abstract] [Full Text] [Related]

  • 18. Uncovering the Expression Pattern of the Costimulatory Receptors ICOS, 4-1BB, and OX-40 in Exhausted Peripheral and Tumor-Infiltrating Natural Killer Cells from Patients with Cervical Cancer.
    Rojas-Diaz JM, Solorzano-Ibarra F, Garcia-Barrientos NT, Klimov-Kravtchenko K, Guitron-Aviña MS, Cruz-Ramos JA, Ortiz-Lazareno PC, Urciaga-Gutierrez PI, Bueno-Topete MR, Garcia-Chagollan M, Haramati J, Del Toro-Arreola S.
    Int J Mol Sci; 2024 Aug 12; 25(16):. PubMed ID: 39201462
    [Abstract] [Full Text] [Related]

  • 19. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.
    Clin Cancer Res; 2013 Nov 15; 19(22):6151-62. PubMed ID: 24030703
    [Abstract] [Full Text] [Related]

  • 20. Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties.
    Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S.
    J Immunother Cancer; 2021 Dec 15; 9(12):. PubMed ID: 34903555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.